Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 berotralstat pediatric prophylaxis study in hereditary angioedema
2021-005932-50Phase 3Active
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Pharmacokinetic profile of berotralstat. Started Apr 2022; status: active.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2021-005932-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005932-50.